• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.

    4/30/25 5:02:29 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIST alert in real time by email
    DEFA14A 1 tm2513454d5_defa14a.htm DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

     

    Filed by the Registrant x
     
    Filed by a Party other than the Registrant ¨
     
    Check the appropriate box:
     
    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    MILESTONE PHARMACEUTICALS INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):
     
    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

    Exhibit 1

    GRAPHIC

    Milestone Pharmaceuticals Inc. Shareholder Meeting Notice 02306A Fold Fold IMPORTANT ANNUAL MEETING INFORMATION Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Shareholders of Milestone Pharmaceuticals Inc. to be Held on June 10, 2025 We are using the U.S. “notice-and-access” system for delivery of the proxy materials relating to this year’s annual meeting of shareholders. Under Securities and Exchange Commission rules, instead of receiving a paper copy of the proxy materials you are receiving this notice that the proxy materials for the annual meeting of shareholders are available on the Internet. Follow the instructions below to view the materials and vote online or request a paper copy. The items to be voted on and the location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to shareholders are available at: www.envisionreports.com/milestone2025 Easy Online Access — A Convenient Way to View Proxy Materials and Vote When you go online to view the proxy materials, you can also vote your shares. Step 1: Go to www.envisionreports.com/milestone2025 to view the proxy materials. Step 2: Click on Cast Your Vote. Step 3: Follow the instructions on the screen to log in. Step 4: Make your selection as instructed on each screen to select delivery preferences and vote. You may also access our proxy materials in the investor relations section of our website at www.milestonepharma.com and under our issuer profile at www.sedarplus.com. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Obtaining a Paper Copy of the Proxy Materials – If you want to receive a paper copy of the proxy materials, you must request one. There is no charge to you for requesting a paper copy. Please make your request for a paper copy as instructed on the reverse side on or before May 27, 2025 to facilitate timely delivery. Vote by Internet • Go to www.envisionreports.com/milestone2025 • Or scan the QR code with your smartphone • Follow the steps outlined on the secure website UMPQ

    GRAPHIC

    Milestone Pharmaceuticals Inc. Shareholder Meeting Notice Milestone Pharmaceuticals Inc. 2025 Annual Meeting of Shareholders will be held on June 10, 2025 via a virtual meeting portal at https://meetnow.global/M7XP457. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations, where applicable. The Board of Directors recommends that you vote FOR Proposals 1, 2, 3 and 4 and 1 YEAR for Proposal 5. 1. Election of Directors. Nominees: Stuart M. Duty Seth H.Z. Fischer Lisa M. Giles Joseph Oliveto Joseph C. Papa Andrew R. Saik Michael Tomsicek Robert J. Wills, Phd 2. Appoint PricewaterhouseCoopers LLP as auditors. 3. Approve the Company’s 2019 Equity Incentive Plan, as amended, to remove the evergreen provision and increase the number of shares authorized for issuance by 4.0 million shares. 4. Advisory approval of the compensation paid to our named executive officers. 5. Advisory vote on the frequency of the advisory vote on compensation paid to our named executive officers. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online, by telephone or request a paper copy of the proxy materials to receive a proxy card. Your online or telephonic vote or completed proxy card must be received by 5:00 p.m. (Eastern Time) on June 6, 2025 or, if the meeting is adjourned or postponed, your online or telephonic vote or completed proxy card must be received at least 48 hours, excluding Saturdays, Sundays and applicable holidays, before the reconvened meeting. If you wish to appoint a person to attend and vote at the meeting on your behalf, please follow the instructions online or on the proxy card to appoint such person. Please review the proxy materials before voting. For directions and additional information regarding attending the meeting, please consult the proxy materials or contact Investor Relations at [email protected]. Here’s how to order a paper copy of the proxy materials and select a future delivery preference: Paper copies: Current and future paper delivery requests can be submitted via the telephone, Internet or email options below. Email copies: Current and future email delivery requests must be submitted via the Internet following the instructions below. If you request an email copy of current proxy materials you will receive an email with a link to the materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a set of proxy materials. g Internet – Go to www.envisionreports.com/milestone2025. Click Cast Your Vote. Follow the instructions to log in and order a paper copy of the current proxy materials and submit your preference for email or paper delivery of future proxy materials. g Telephone – Call us free of charge at within North America - 1-866-962-0498 or direct, from Outside of North America - (514) 982-8716 and follow the instructions to log in and order a paper copy of the proxy materials by mail for the current meeting. You can also submit a preference to receive a paper copy for future meetings. g Email – Send email to [email protected] with “Proxy Materials Milestone Pharmaceuticals Inc.” in the subject line. Include in the message your full name and address, plus the number located in the shaded bar on the reverse side, and state in the email that you want a paper copy of current proxy materials. You can also state your preference to receive a paper copy for future meetings. g If you have questions about electronic delivery of proxy materials, you can also call Milestone Investor Relations at (514) 336-0444 or send an email to [email protected]. To facilitate timely delivery, all requests for a paper copy of the proxy materials must be received on or before May 27, 2025. 02307A

    Get the next $MIST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MIST

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/20/2023$8.00 → $4.00Buy → Hold
    Jefferies
    4/22/2022$8.00 → $10.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $MIST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      8/22/24 7:32:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Milestone Pharmaceuticals from Buy to Hold and set a new price target of $4.00 from $8.00 previously

      6/20/23 7:40:01 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Milestone Pharmaceuticals from Neutral to Overweight and set a new price target of $10.00 from $8.00 previously

      4/22/22 7:40:09 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Leadership Updates

    Live Leadership Updates

    See more
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

      MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

      9/4/24 8:00:00 AM ET
      $CADL
      $EBS
      $MIST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update

      -       RAPID topline data readout remains on track for mid-second half 2022 -       Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update. "The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT," said Josep

      5/12/22 7:15:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the Jefferies Healthcare Conference, to take place June 3 - 5, 2025, in New York. A webcast of the presentation will be available on June 5th at 8:10 AM EDT. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach out to your Jef

      5/28/25 8:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

      Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL issues. "Our immediate priority is to engage with the U.S. FDA in order to address the CMC-related issues raised in the CRL received for CARDAMYST as a treatment for PSVT," said Joe Oliveto, President and Chief Executiv

      5/14/25 7:04:55 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

      Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

      4/10/25 8:30:00 AM ET
      $ACOG
      $CBAY
      $MIST
      $ONCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

      SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      10/29/24 4:30:20 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

      SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      7/16/24 6:06:24 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

      2/14/24 8:56:08 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    SEC Filings

    See more
    • Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

      5/14/25 7:11:58 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Milestone Pharmaceuticals Inc.

      10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

      5/14/25 7:00:28 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.

      DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

      4/30/25 5:02:29 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Nelson Jeffrey Edward

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:17 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Muller Lorenz

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:15 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CFO & EVP of Corp. Development Hasija Amit

      4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

      1/29/25 4:15:15 PM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MIST
    Financials

    Live finance-specific insights

    See more
    • Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

      New Drug Application submitted to the U.S. Food and Drug Administration for CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, for patients with PSVT Positive Phase 2 data evaluating etripamil in AFib-RVR were a Featured Science Presentation at 2023 AHA Scientific Sessions; Phase 3 program expected to begin enrollment in mid-2024Company to host Investor and Analyst Webcast to review data from ReVeRA Phase 2 study of etripamil in atrial fibrillation with rapid ventricular rate today at 8:00 a.m. ETMONTREAL and CHARLOTTE, N.C., Nov. 13, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today reported financial results for the third quarter ended Septem

      11/13/23 6:57:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

      -  Self-administration of etripamil in patients experiencing AFib-RVR episodes resulted in a substantial reduction in ventricular rate which was sustained over 60 minutes -  Data featured in an oral session at the Heart Rhythm 2023 Annual Meeting -  Company to host virtual KOL conference call and webcast to discuss etripamil development for the treatment of AFib-RVR today at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 22, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced promising data from an ad hoc analysis of a subset of patients experien

      5/22/23 7:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

      -  Cardiac Electrophysiology Key Opinions Leaders to include Paul Dorian, MD, and Jonathan Piccini, MD -  Conference call and webcast on Monday, May 22, 2023 at 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., May 8, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Monday, May 22, 2023 at 8:00 a.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the potential treatment of patients with atrial fibrillation (AFib) and rapid ventricular rate (A

      5/8/23 7:00:00 AM ET
      $MIST
      Biotechnology: Pharmaceutical Preparations
      Health Care